Examination of Efficacy and Safety of Baricitinib in RA Patients

Shinshu University

Status and phase: Enrolling; Phase 2

Conditions: Rheumatoid Arthritis

Treatments: Drug: Tofacitinib 5 MG [Xeljanz]; Drug: "Baricitinib", "olumiant®"; Drug: "Biologics"

Study type: Interventional

Funder types: Other

Identifiers

NCT03755466

BARI2018

Details and patient eligibility

About

The aim of this study is to examine the efficacy and adverse events in the following 3 groups in rheumatoid arthritis patients:

1. Baricitinib treatment for 12 months
2. Biologics treatment for 12 months
3. Tofacitinib treatment for 12 months

Enrollment: 90 estimated patients

Sex: All

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• RA patients

Exclusion criteria

• Not RA patients
• RA patients who are allergic to the drugs, refused to do this research, or who are pregnant

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

90 participants in 3 patient groups

BARI

Active Comparator group

Treatment:

Drug: "Biologics"

Drug: Tofacitinib 5 MG [Xeljanz]

Bio

Active Comparator group

Treatment:

Drug: Tofacitinib 5 MG [Xeljanz]

Drug: "Baricitinib", "olumiant®"

Tofa

Active Comparator group

Treatment:

Drug: "Biologics"

Drug: "Baricitinib", "olumiant®"